{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:29:16Z","timestamp":1786555756444,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373252"],"award-info":[{"award-number":["82373252"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203881"],"award-info":[{"award-number":["82203881"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92459302"],"award-info":[{"award-number":["92459302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20327"],"award-info":[{"award-number":["U22A20327"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Notification of application for National Science and Technology Innovation 2030, Major Project- Research on Cancer, Cardiovascular, Respiratory and Metabolic Diseases","award":["2023ZD0501602"],"award-info":[{"award-number":["2023ZD0501602"]}]},{"name":"Young elite scientist sponsorship program by cast","award":["No. YESS20240505"],"award-info":[{"award-number":["No. YESS20240505"]}]},{"name":"Peking University Cancer Hospital Young Scientific Research Talent Cultivation Program","award":["BJCH2025GG03"],"award-info":[{"award-number":["BJCH2025GG03"]}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2026-1Q-1093"],"award-info":[{"award-number":["2026-1Q-1093"]}]},{"name":"Peking University Medicine Sailing Program for Young Scholars\u2019 Scientific & Technological Innovation, the Fundamental Research Funds for the Central University","award":["BMU2025YFJHPY039"],"award-info":[{"award-number":["BMU2025YFJHPY039"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01405-0","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:10:01Z","timestamp":1782925801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation"],"prefix":"10.1007","volume":"39","author":[{"given":"Lei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5953-5225","authenticated-orcid":false,"given":"Huan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1405_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386.","journal-title":"Signal Transduct Target Ther"},{"key":"1405_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","volume":"37","author":"M Drosten","year":"2020","unstructured":"Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37:543\u201350.","journal-title":"Cancer Cell"},{"key":"1405_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41698-021-00237-5","volume":"5","author":"G Palma","year":"2021","unstructured":"Palma G, Khurshid F, Lu K, Woodward B, Husain H. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. NPJ Precision Oncolo. 2021;5:98.","journal-title":"NPJ Precision Oncolo"},{"key":"1405_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/cac2.70056","volume":"45","author":"J Li","year":"2025","unstructured":"Li J, Deng T, Gu Y, Calles BA, Li Z, Bai C, et al. Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: a pooled analysis of two phase I\/II trials. Cancer Commun (Lond). 2025;45:1500\u201312.","journal-title":"Cancer Commun (Lond)"},{"key":"1405_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20:143.","journal-title":"Mol Cancer"},{"key":"1405_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1200\/JCO.2023.41.4_suppl.41","volume":"41","author":"H Hsu","year":"2023","unstructured":"Hsu H, Aggarwal S, Balan A, Ricciuti B, Egger JV, LeNoue-Newton M, et al. Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C\u2013mutated metastatic colorectal cancer in AACR Project GENIE. J Clin Oncol. 2023;41:41.","journal-title":"J Clin Oncol"},{"key":"1405_CR7","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022;28:1482\u20136.","journal-title":"Clin Cancer Res"},{"key":"1405_CR8","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus Panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;389:2125\u201339.","journal-title":"N Engl J Med"},{"key":"1405_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(25)00267-5","author":"J Li","year":"2025","unstructured":"Li J, Wang Z, Huang J, Ba Y, Cao B, Luo S, et al. Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS(G12C) mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1\/2 trials. Lancet Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/s2468-1253(25)00267-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1405_CR10","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41591-019-0593-1","volume":"25","author":"F Chemi","year":"2019","unstructured":"Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019;25:1534\u20139.","journal-title":"Nat Med"},{"key":"1405_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","volume":"6","author":"D Lin","year":"2021","unstructured":"Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6:404.","journal-title":"Signal Transduct Target Ther"},{"key":"1405_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1126\/science.1228522","volume":"339","author":"M Yu","year":"2013","unstructured":"Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580\u20134.","journal-title":"Science"},{"key":"1405_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101119","volume":"76","author":"A Hariri","year":"2024","unstructured":"Hariri A, Mirian M, Khosravi A, Zarepour A, Iravani S, Zarrabi A. Intersecting pathways: The role of hybrid E\/M cells and circulating tumor cells in cancer metastasis and drug resistance. Drug Resist Updat. 2024;76:101119.","journal-title":"Drug Resist Updat"},{"key":"1405_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-024-01637-3","volume":"17","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhang X, Lv Z, Huo H, Yuan L, Wan D, et al. Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma. J Hematol Oncol. 2024;17:114.","journal-title":"J Hematol Oncol"},{"key":"1405_CR15","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.7150\/ijbs.71768","volume":"18","author":"Z Feng","year":"2022","unstructured":"Feng Z, Wu J, Lu Y, Chan YT, Zhang C, Wang D, et al. Circulating tumor cells in the early detection of human cancers. Int J Biol Sci. 2022;18:3251\u201365.","journal-title":"Int J Biol Sci"},{"key":"1405_CR16","doi-asserted-by":"publisher","first-page":"1238332","DOI":"10.3389\/fonc.2023.1238332","volume":"13","author":"S Cai","year":"2023","unstructured":"Cai S, Deng Y, Wang Z, Zhu J, Huang C, Du L, et al. Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis. Front Oncol. 2023;13:1238332.","journal-title":"Front Oncol"},{"key":"1405_CR17","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00432-013-1450-0","volume":"139","author":"P Gazzaniga","year":"2013","unstructured":"Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, et al. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? J Cancer Res Clin Oncol. 2013;139:1411\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1405_CR18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/cells12081172","volume":"12","author":"V Magri","year":"2023","unstructured":"Magri V, Marino L, Nicolazzo C, Gradilone A, De Renzi G, De Meo M, et al. Prognostic role of circulating tumor cell trajectories in metastatic colorectal cancer. Cells. 2023;12:1172.","journal-title":"Cells"},{"key":"1405_CR19","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","volume":"26","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26:3213\u201321.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1405_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12943-025-02465-w","volume":"24","author":"X Ren","year":"2025","unstructured":"Ren X, Song M, Liu X, He W. Circulating tumor cells: mechanisms and clinical significance in colorectal cancer metastasis. Mol Cancer. 2025;24:242.","journal-title":"Mol Cancer"},{"key":"1405_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4275","volume":"5","author":"X Liu","year":"2019","unstructured":"Liu X, Li J, Cadilha BL, Markota A, Voigt C, Huang Z, et al. Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Sci Adv. 2019;5:v4275.","journal-title":"Sci Adv"},{"key":"1405_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10555-024-10198-3","volume":"43","author":"Y Qiu","year":"2024","unstructured":"Qiu Y, Gao T, Smith BR. Mechanical deformation and death of circulating tumor cells in the bloodstream. Cancer Metastasis Rev. 2024;43:1489\u2013510.","journal-title":"Cancer Metastasis Rev"},{"key":"1405_CR23","doi-asserted-by":"publisher","first-page":"1099921","DOI":"10.3389\/fimmu.2023.1099921","volume":"14","author":"JM Rozenberg","year":"2023","unstructured":"Rozenberg JM, Buzdin AA, Mohammad T, Rakitina OA, Didych DA, Pleshkan VV, et al. Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers. Front Immunol. 2023;14:1099921.","journal-title":"Front Immunol"},{"key":"1405_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/HEP.0000000000000934","volume":"81","author":"Y Sun","year":"2025","unstructured":"Sun Y, Li T, Ding L, Wang J, Chen C, Liu T, et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatol. 2025;81:791\u2013807.","journal-title":"Hepatol"},{"key":"1405_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.62347\/JAYK5667","volume":"15","author":"J Yang","year":"2025","unstructured":"Yang J, Xu P, Zhang G, Wang D, Ye B, Wu L. Advances and potentials in platelet-circulating tumor cell crosstalk. Am J Cancer Res. 2025;15:407\u201325.","journal-title":"Am J Cancer Res"},{"key":"1405_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117474","volume":"180","author":"C Hu","year":"2024","unstructured":"Hu C, Long L, Lou J, Leng M, Yang Q, Xu X, et al. CTC-neutrophil interaction: a key driver and therapeutic target of cancer metastasis. Biomed Pharmacother. 2024;180:117474.","journal-title":"Biomed Pharmacother"},{"key":"1405_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18:64.","journal-title":"Mol Cancer"},{"key":"1405_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41392-023-01725-9","volume":"8","author":"Q Zhan","year":"2023","unstructured":"Zhan Q, Liu B, Situ X, Luo Y, Fu T, Wang Y, et al. New insights into the correlations between circulating tumor cells and target organ metastasis. Signal Transduction Targeted Ther. 2023;8:465.","journal-title":"Signal Transduction Targeted Ther"},{"key":"1405_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goac083","volume":"11","author":"M-H Zhao","year":"2023","unstructured":"Zhao M-H, Wu A-W. Targeting KRAS G12C mutations in colorectal cancer. Gastroenterol Rep. 2023;11:goac083.","journal-title":"Gastroenterol Rep"},{"key":"1405_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Mezzadra R, Sinopoli J, Bian Y, Marasco M, Kaplun E, et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov. 2023;13:41\u201355.","journal-title":"Cancer Discov"},{"key":"1405_CR31","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00384-014-1958-z","volume":"29","author":"E Magni","year":"2014","unstructured":"Magni E, Botteri E, Ravenda PS, Cassatella MC, Bertani E, Chiappa A, et al. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int J Colorectal Dis. 2014;29:1053\u20139.","journal-title":"Int J Colorectal Dis"},{"key":"1405_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1186\/s12967-023-04619-0","volume":"21","author":"PA Laurent","year":"2023","unstructured":"Laurent PA, Milic M, Quevrin C, Meziani L, Liu W, Morel D, et al. KRAS(G12C) inhibition using MRTX1257: a novel radio-sensitizing partner. J Transl Med. 2023;21:773.","journal-title":"J Transl Med"},{"key":"1405_CR33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","volume":"20","author":"DM Briere","year":"2021","unstructured":"Briere DM, Li S, Calinisan A, Sudhakar N, Aranda R, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol Cancer Ther. 2021;20:975\u201385.","journal-title":"Mol Cancer Ther"},{"key":"1405_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40265-024-02030-7","volume":"84","author":"J Torres-Jim\u00e9nez","year":"2024","unstructured":"Torres-Jim\u00e9nez J, Espinar JB, de Cabo HB, Berjaga MZ, Esteban-Villarrubia J, Fraile JZ, et al. Targeting KRAS(G12C) in non-small-cell lung cancer: current standards and developments. Drugs. 2024;84:527\u201348.","journal-title":"Drugs"},{"key":"1405_CR35","doi-asserted-by":"publisher","first-page":"66r","DOI":"10.1126\/scitranslmed.3002543","volume":"3","author":"J Wu","year":"2011","unstructured":"Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:66r\u201392r.","journal-title":"Sci Transl Med"},{"key":"1405_CR36","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379\u201388.","journal-title":"Clin Cancer Res"},{"key":"1405_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403:171\u201382.","journal-title":"Lancet"},{"key":"1405_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2026.111519","volume":"219","author":"DG Miller","year":"2026","unstructured":"Miller DG, Zhang YH, Thor M, Shin JY, Imber BS, Offin MD, et al. Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2026;219:111519.","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"}],"updated-by":[{"DOI":"10.1007\/s13577-026-01434-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000}}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01405-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01405-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01405-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:31:22Z","timestamp":1786552282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01405-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1405"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01405-0","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13577-026-01434-9","URL":"https:\/\/doi.org\/10.1007\/s13577-026-01434-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.H., H.Z. and Z.L. were employed by the company Cellomics ShenZhen Limited. Other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate. The study was approved by the Institutional Ethics Committee of our hospital. Written consent forms were received from each patient before specimen collection (2021YW103-ZY16, 2021YW286-ZY07).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yes.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"95"}}